We have detected that you are using Internet Explorer to visit this website. Internet Explorer is now being phased out by Microsoft. As a result, NHS Digital no longer supports any version of Internet Explorer for our web-based products, as it involves considerable extra effort and expense, which cannot be justified from public funds. Some features on this site will not work. You should use a modern browser such as Edge, Chrome, Firefox, or Safari. If you have difficulty installing or accessing a different browser, contact your IT support team.
National Diabetes Audit Report 1 - Care Processes and Treatment Targets 2018-19, Short ReportAudit
- Publication Date:
- 13 Dec 2019
- Geographic Coverage:
- England, Wales
- Geographical Granularity:
- Clinical Commissioning Groups, GP practices, Hospital Trusts
- Date Range:
- 01 Jan 2018 to 31 Mar 2019
The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England and the Welsh Government. The NDA is managed by NHS Digital in partnership with Diabetes UK.
The NDA measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards, in England and Wales. The NDA collects and analyses data for use by a range of stakeholders to drive changes and improvements in the quality of services and health outcomes for people with diabetes.
This short report details the top-level findings for the 2018-19 audit. The audit collected data during May and June 2019, for the period 01 January 2018 to 31 March 2019. The top-level findings below, along with supporting data at Clinical Commissioning Group (CCG), Local Health Board (LHB), GP practice and specialist diabetes service have been made available to provide data back to services in a timely manner that can help drive improvements in the quality of diabetes care locally.
The full report, scheduled for 2020, will contain full key findings, recommendations and results of new analyses into HbA1c check frequencies and blood glucose drug cohorts. We will communicate to users when the date for this report has been finalised.
A new method of collecting structured education attendance data was trialled for 2018-19. In addition to extracting education data from GP practice systems, structured education providers could submit data directly via the Clinical Audit Platform (CAP). Around 20 providers submitted, however only a small proportion of records were submitted with the required data. This exercise has shown the potential value of this additional collection and improvements to the process are being developed to improve future collections.
• GP practice participation in England and Wales stands at 98.0 per cent for 2018-19.
• Diabetes specialist service participation increased from 101 in 2017-18 to 112 in 2018-19.
• In England, the percentage of people who had all eight care process checks during 2018-19 stands at 40.8 per cent for people with Type 1 diabetes (42.9 per cent in 2017-18) and 54.3 per cent for people with Type 2 and other diabetes (58.8 per cent in 2017-18).
• In Wales, the percentage of people who had all eight care process checks during 2018-19 stands at 23.3 per cent for people with Type 1 diabetes (24.7 per cent in 2017-18) and 44.7 per cent for people with Type 2 and other diabetes (45.9 per cent in 2017-18).
• In England, the percentage of people who met the new all three treatment targets* during 2018-19 stands at 19.6 per cent for people with Type 1 diabetes (18.9 per cent in 2017-18) and 40.5 per cent for people with Type 2 and other diabetes (40.2 per cent in 2017-18).
• In Wales, the percentage of people who met the new all three treatment targets* during 2018-19 stands at 15.1 per cent for people with Type 1 diabetes (15.2 per cent in 2017-18) and 33.6 per cent for people with Type 2 and other diabetes (35.0 per cent in 2017-18).
* HbA1c value ≤ 58mmol/mol, blood pressure ≤140/80 and, for people who fall into the combined prevention of cardiovascular disease risk group, is receiving statins.